22 nonprofit healthcare leaders who sit on pharma boards

Twelve of the 19 largest pharmaceutical and biotech companies have at least one director serving on their board who simultaneously serves in a leadership position at a healthcare system, according to BioPharma Dive.

In addition, 22 directors total hold positions at pharma companies and healthcare nonprofits. Below is a breakdown of the leaders, including their position at the healthcare company, the drugmaker they help lead,  the number of shares they own at the drugmaker andthe amount they earned from the pharma company in 2017.

Companies included on BioPharma's list were publicly traded with a market value of at least $35 billion. Share prices were calculated using Nov. 27 market close values. In addition, BioPharma qualified leaders of nonprofits as directors, CEOs or those who hold executive positions.

Here are the leaders:

1. Robert Alpern, MD — Dean of Yale School of Medicine (New Haven, Conn.)

Drugmaker: AbbVie
Compensation: $335,929
Shares Value: $4.3 million

2. Nesli Basgoz, MD  — Associate chief and clinical director of Massachusetts General Hospital's infectious disease division (Boston)

Drugmaker: Allergan
Compensation: $473,941
Shares Value: $906,701

3. Michael Greenberg, PhD — Co-leader of Harvard Medical School and Boston Children's Hospital's Allen Discovery Center for Human Brain Evolution

Drugmaker: Allergan
Compensation: Not applicable, joined board in August 2018
Shares Value: Not applicable, joined board in August 2018

4. Peter McDonnell, MD — Director of the Wilmer Eye Institute at the Johns Hopkins University School of Medicine (Baltimore)

Drugmaker: Allergan
Compensation: $449,941
Shares Value: $735,307

5. Brian Druker, MD — Director of the Knight Cancer Institute at the Oregon Health & Science University (Portland)

Drugmaker: Amgen
Compensation: Not applicable, joined board in August 2018
Shares Value: Not applicable, joined board in August 2018

6. Tyler Jacks, PhD — Director of David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (Cambridge)

Drugmaker: Amgen
Compensation: $343,998
Shares Value: $1.15 million

7. Julia Haller, MD — Ophthalmologist-in-chief at Wills Eye Hospital (Philadelphia)

Drugmaker: Celgene
Compensation: $525,470
Shares Value: $86,487

8. Marschall Runge, MD, PhD — Dean of University of Michigan Medical School (Ann Arbor)

Drugmaker: Eli Lilly
Compensation: $279,000
Shares Value: $1.07 million

9. Kevin Lofton — CEO of Catholic Health Initiatives (Englewood, Colo.)
Drugmaker: Gilead Sciences
Compensation: $415,803
Shares Value: $1.81 million

10. Richard Whitley, MD — Associate director for drug discovery and development for University of Alabama (Birmingham) Comprehensive Cancer Center
Drugmaker: Gilead
Compensation: $430,803
Shares Value: $709,469

11. Laurie Glimcher, MD —President and CEO of the Dana-Farber Cancer Institute (Boston)

Drugmaker: GlaxoSmithKline
Compensation: $101,000 prorated
Shares Value: $75,707

12. Jesse Goodman, MD — Director of Georgetown University's Center on Medical Product Access, Safety and Stewardship (Washington, D.C.)

Drugmaker: GlaxoSmithKline
Compensation: $428,000
Shares Value: $130,799

13. Mary Beckerle, PhD — CEO of Huntsman Cancer Institute at the University of Utah (Salt Lake City)

Drugmaker: Johnson & Johnson
Compensation: $324,893
Shares Value: $672,418

14. Mark McClellan, MD, PhD —Director of Margolis Center for Health Policy at Duke University (Durham, N.C.)

Drugmaker: Johnson & Johnson
Compensation: $284,893
Shares Value: $1.19 million

15. A. Eugene Washington, MD — President and CEO of the Duke University Health System (Durham) and the university's chancellor for health affairs

Drugmaker: Johnson & Johnson
Compensation: $284,893
Shares Value: $2.33 million

16. Thomas Cech, PhD — Director of the BioFronteirs Institute at University of Colorado-Boulder

Drugmaker: Merck & Co.
Compensation: $318,465
Shares Value: $2.3 million

17. John Noseworthy, MD — CEO of Mayo Clinic (Rochester, Minn.)

Drugmaker: Merck
Compensation: $234,167 prorated
Shares Value: $293,680

18. Charles Sawyers, MD —Chair of Human Oncology and Pathogenesis at Memorial Sloan Kettering Cancer Center (New York City)

Drugmaker: Novartis
Compensation: $367,000
Shares Value: $690,131

19. Dennis Ausiello, MD — Director for Assessment Technology and Continuous Health at Massachusetts General Hospital (Boston)

Drugmaker: Pfizer
Compensation: $375,000
Shares Value: $1.9 million

20. Michael Brown, PhD — Director for the Erik Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical Center (Dallas)

Drugmaker: Regeneron
Compensation: $1.32 million
Shares Value: $4.37 million

21. Joseph Goldstein, MD — Chairman of the molecular genetics department at the University of Texas Southwestern Medical Center (Dallas)

Drugmaker: Regeneron
Compensation: $1.31 million
Shares Value: $4.24 million

22. Huda Zoghbi, MD — Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital (Houston)

Drugmaker: Regeneron
Compensation: $463,656
Share Value: $0

Seven of the 19 companies analyzed in this report — San Sanofi, Novo Nordisk, Bristol-Myers Squibb, AstraZeneca, Biogen, Shire and Vertex —had no current leaders of healthcare nonprofits serving on their boards.

Read the full report here.

More articles on pharmacy:
Teva launches generic EpiPen for $300
Bayer considers sale of consumer health brands
Unilever wants to buy GlaxoSmithKline's nutrition business: 5 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars